565
Views
4
CrossRef citations to date
0
Altmetric
Short Report

Long-term silencing of autoimmune diabetes and improved life expectancy by a soluble pHLA-DR4 chimera in a newly-humanized NOD/DR4/B7 mouse

, , &
Pages 693-699 | Received 29 Oct 2013, Accepted 28 Nov 2013, Published online: 11 Dec 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Takeshi Susukida, Shigeki Aoki, Tomohiro Shirayanagi, Yushiro Yamada, Saki Kuwahara & Kousei Ito. (2020) HLA transgenic mice: application in reproducing idiosyncratic drug toxicity. Drug Metabolism Reviews 52:4, pages 540-567.
Read now

Articles from other publishers (3)

Miriam Cabello-Olmo, Miriam Araña, Ilian Radichev, Paul Smith, Eduardo Huarte & Miguel Barajas. (2019) New Insights into Immunotherapy Strategies for Treating Autoimmune Diabetes. International Journal of Molecular Sciences 20:19, pages 4789.
Crossref
Mirian Mendoza, Luis Pow Sang, Qi Qiu, Sofia Casares & Teodor-D. Brumeanu. (2016) Nonobese Diabetic (NOD) Mice Lack a Protective B-Cell Response against the “Nonlethal” Plasmodium yoelii 17XNL Malaria Protozoan . Malaria Research and Treatment 2016, pages 1-9.
Crossref
James A. Pearson, F. Susan Wong & Li Wen. (2016) The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes. Journal of Autoimmunity 66, pages 76-88.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.